BostonGene teams up with AstraZeneca on AI-driven oncology

US biotech BostonGene has struck a research collaboration with British pharma AstraZeneca (LSE: AZN) to explore the use of multimodal artificial intelligence in oncology drug development. The partners will apply BostonGene’s AI platform to forecast patient-level outcomes, accelerate clinical trials and reduce development risk. Financial terms were not disclosed.

Under the agreement, AstraZeneca will use BostonGene’s omnimodal analytics to generate predictive insights on safety and efficacy in early-stage oncology studies. Jorge Reis-Filho, chief of AI for science innovation at AstraZeneca, said the collaboration would “empower us to predict which patients will benefit from treatment, helping us design safer, more effective therapies from the start.”

BostonGene’s platform combines bioinformatics, next-generation sequencing, flow cytometry and imaging to generate molecular and cellular insights. It integrates multimodal datasets, including cell-free nucleic acids and tumor microenvironment profiling, to predict drug response and tolerability across diverse patient populations.